Who owns BioCryst Pharmaceuticals?

Key details on BioCryst Pharmaceuticals (Ticker: BCRX)

Who owns BioCryst Pharmaceuticals?

Is BCRX a good stock to own? Find out who bought BioCryst Pharmaceuticals, who sold BioCryst Pharmaceuticals (BCRX) stock, and who holds a large position in BioCryst Pharmaceuticals.

Fund Name Number of Shares Share Valuation As Of
FMR 8.99M $95.14M March 31, 2014
Baker Bros. Advisors 5.87M $62.07M March 31, 2014
RA Capital Management 4.35M $46.00M March 31, 2014
Wellington Management Company 4.02M $42.53M March 31, 2014
D. E. Shaw & Co 2.07M $21.89M March 31, 2014
Vanguard 1.78M $18.86M March 31, 2014
SUSQUEHANNA INTERNATIONAL 1.74M $18.46M March 31, 2014
VHCP Management 1.74M $18.46M March 31, 2014
STATE STREET CORPORATION 1.64M $17.33M March 31, 2014
T. Rowe Price Associates 1.58M $16.75M March 31, 2014
Cormorant Asset Management 1.17M $12.36M March 31, 2014
TPG Group Holdings 1.16M $12.30M March 31, 2014
TPG Capital 1.16M $3.21M Sept. 30, 2011
BlackRock Institutional Trust Company, N.A. 1.08M $11.42M March 31, 2014
Deerfield Management Company 907920 $9.61M March 31, 2014
BlackRock Fund Advisors 898132 $9.50M March 31, 2014
Driehaus Capital Management 702175 $2.98M Sept. 30, 2012
Millennium Management 589752 $6.24M March 31, 2014
Connor, Clark & Lunn Investment Management 528098 $6.17M March 31, 2014
QVT Financial 525734 $5.56M March 31, 2014
MORGAN STANLEY 525306 $5.56M March 31, 2014
Barclays 516100 $2.49M March 31, 2012
Technical Financial Services 499516 $3.80M Dec. 31, 2013
NORTHERN TRUST 495047 $762372 June 30, 2013
BOGLE INVESTMENT MANAGEMENT L P /DE/ 386089 $2.81M Sept. 30, 2013
Jennison Associates 358557 $3.79M March 31, 2014
Connor, Clark & Lunn Investment Management 316878 $2.56M Dec. 31, 2013
Thomson Horstmann & Bryant, Inc." 301529 $3.19M March 31, 2014
Oxford Asset Management 293605 $3.73M June 30, 2014
SMITH ASSET MANAGEMENT 291983 $2.22M Dec. 31, 2013
FRANKLIN STREET ADVISORS INC /NC 289550 $1.23M Sept. 30, 2012
Geode Capital Management 278664 $2.95M March 31, 2014
PanAgora Asset Management 246190 $2.60M March 31, 2014
TIAA-CREF Investment Management 235008 $279659 March 31, 2013
Visium Asset Management 234900 $1.79M Dec. 31, 2013
Jacobs Levy Equity Management 233447 $989815 Sept. 30, 2012
Sunrise Partners Limited Partnership 229064 $355049 June 30, 2013
UBS AG 228557 $354263 June 30, 2013
GOLDMAN SACHS 206775 $320501 June 30, 2013
Perceptive Advisors 197500 $1.50M Dec. 31, 2013
JPMORGAN CHASE & CO 191350 $759659 June 30, 2012

Who sold BioCryst Pharmaceuticals?

Fund Name Date Sold Number of Shares Sold Share Valuation
BAM Capital Dec. 31, 2010 861485 $4.45M